Business
Dr Reddy’s to exclusively distribute Sanofi’s vaccine portfolio in India – Times of India
[ad_1]
HYDERABAD: Dr Reddy’s Laboratories on Wednesday informed the bourses has entered into an exclusive partnership with Sanofi Healthcare India Pvt Ltd for the distribution of the latter’s vaccine portfolio in the Indian market.
As part of the agreement, while Dr Reddy’s will have exclusive rights to promote and distribute Sanofi’s paediatric and adult vaccine brands in India, Sanofi will continue to own, manufacture, and import these brands to the country.
These include paediatric and adult vaccine brands such as Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U. These brands rang up combined sales of around Rs 426 crore (approx. US$51 million), as per IQVIA MAT February 2024.
The Hyderabad-based pharma major said the partnership is part of Dr Reddy’s efforts to emerge as the partner of choice in increasing access to novel, innovative and trusted drugs for patients in India.
The alliance will give it a strong portfolio and a major presence in the vaccine segment, propelling it to second position among vaccine players in the country.
Pointing out that the Sanofi portfolio will give the company’s presence in the vaccine segment a strong boost, Dr Reddy’s Labs CEO for branded markets (India and emerging markets) MV Ramana said the company will get an opportunity to leverage its strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi’s well-established and trusted vaccine brands in India.
“We continue our efforts to become the partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic collaborations,” he added.
Pointing out that the alliance with Dr Reddy’s will help Sanofit expand its geographic reach in the Indian market, Preeti Futnani, general manager for vaccines in India at Sanofi, said though vaccine confidence has reached its highest in India in the last few years, still a lot remains to be done for the rest of the country’s large unvaccinated population.
As part of the agreement, while Dr Reddy’s will have exclusive rights to promote and distribute Sanofi’s paediatric and adult vaccine brands in India, Sanofi will continue to own, manufacture, and import these brands to the country.
These include paediatric and adult vaccine brands such as Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U. These brands rang up combined sales of around Rs 426 crore (approx. US$51 million), as per IQVIA MAT February 2024.
The Hyderabad-based pharma major said the partnership is part of Dr Reddy’s efforts to emerge as the partner of choice in increasing access to novel, innovative and trusted drugs for patients in India.
The alliance will give it a strong portfolio and a major presence in the vaccine segment, propelling it to second position among vaccine players in the country.
Pointing out that the Sanofi portfolio will give the company’s presence in the vaccine segment a strong boost, Dr Reddy’s Labs CEO for branded markets (India and emerging markets) MV Ramana said the company will get an opportunity to leverage its strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi’s well-established and trusted vaccine brands in India.
“We continue our efforts to become the partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic collaborations,” he added.
Pointing out that the alliance with Dr Reddy’s will help Sanofit expand its geographic reach in the Indian market, Preeti Futnani, general manager for vaccines in India at Sanofi, said though vaccine confidence has reached its highest in India in the last few years, still a lot remains to be done for the rest of the country’s large unvaccinated population.
